There are some noteworthy aspect of the upcoming regulatory jungle. When analysing future business cases for new OTC-derivative products, you need to consider sections on future regulatory impacts! To give an example, the EMIR regulations stipulate a lot of detailed rules, for example actual exchange of collateral, most likely on a daily basis, this already might deter some… Continue reading Chased by the Regulatory wave!
